Clinical trials: Allergic Conjunctivitis
Allergic Conjunctivitis
Safety and Efficacy Study of a Eye Drop for Eye Allergy
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.
- Trial name
- NCT00889330
- Testing
- alcaftadine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vistakon Pharmaceuticals
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis
Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study
TX-SMILE is an investigator-initiated, multi-center, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intra-lymphatic administration of an approved…
- Conditions
- Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
- Trial name
- TX-SMILE (NCT03682965)
- Testing
- Intra-lymphatic allergenic extract
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Christopher Thompson, MD
Allergic Conjunctivitis
Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
The purpose of this study is to evaluate the effectiveness and safety of Olopatadine Hydrochloride (HCl) ophthalmic solution 0.1% versus Epinastine HCl ophthalmic solution, 0.05% in a population of healthy, adult Japanese…
- Trial name
- NCT02251613
- Testing
- Olopatadine HCl ophthalmic solution, 0.1%, Epinastine HCl ophthalmic solution, 0.05%
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- AC-170 (NCT01332188)
- Testing
- AC-170 0.05%, AC-170 0.1%, AC-170 0.24%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Seasonal Allergic Conjunctivitis
Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal…
- Trial name
- NCT01435460
- Testing
- Loteprednol etabonate 0.2%, Olopatadine 0.1%
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- Bausch & Lomb Incorporated
Conjunctivitis, Allergic
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT01470118
- Testing
- alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Allergan
Allergic Conjunctivitis
Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
The purpose of the study is to demonstrate safety and efficacy of DE-114 ophthalmic solution compared to its Placebo and Olopatadine hydrochloride 0.1% ophthalmic solution in patients with allergic conjunctivitis.
- Trial name
- NCT01363700
- Testing
- DE-114 ophthalmic solution, Olopatadine Hydrochloride 0.1% Ophthalmic Solution
- Where
- Japan
- Volunteers
- 87 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Allergic Conjunctivitis
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01551056
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Aciex Therapeutics, Inc.
Allergic Conjunctivitis
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
The purpose of this study is to descriptively evaluate the corneal structures of allergic conjunctivitis patients.
- Trial name
- NCT01697969
- Testing
- Olopatadine hydrochloride ophthalmic solution, 0.2%
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Alcon Research
Conjunctivitis, Allergic
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT01732757
- Testing
- Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Allergan
Chronic Allergic Conjunctivitis
OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of…
- Trial name
- NCT02988882
- Testing
- Dexamethasone
- Volunteers
- 86 people
- Sponsor
- Ocular Therapeutix, Inc.
Conjunctivitis, Allergic
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the prevention of allergen-mediated conjunctivitis.
- Trial name
- NCT02161146
- Testing
- AGN-229666, Vehicle to AGN-229666, Olopatadine
- Where
- Japan
- Volunteers
- 240 people
- Sponsor
- Allergan
Allergic Conjunctivitis
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Allergic conjunctivitis (AC) afflicts approximately 20% of the US population. Typically, patients manifest symptoms in the spring, summer and fall, when airborne allergens are at their peak.
- Trial name
- NCT01443442
- Testing
- bepotastine besilate, 1.5%, Loteprednol etabonate
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Southern California College of Optometry at Marshall B. Ketchum University
Allergic Conjunctivitis
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT00882687
- Testing
- Lifitegrast
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shire
Rhinitis, Allergic, Seasonal
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
The purpose of this study is to assess the safety and tolerability of MK-3641 (short ragweed [Ambrosia artemisiifolia] extract, SCH 039641, RAGWITEK®) sublingual tablets and MK-7243 (Timothy grass [Phleum pratense] extract, SCH…
- Trial name
- NCT02256553
- Testing
- MK-3641 12 Amb a 1-U (short ragweed extract), MK-7243 2800 BAU (Timothy grass extract), Rescue Medication
- Volunteers
- 102 people
- Sponsor
- ALK-Abelló A/S
Allergic Conjunctivitis
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory…
- Trial name
- NCT01534195
- Testing
- Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- ORA, Inc.
Conjunctivitis, Allergic
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
- Trial name
- NCT00424398
- Testing
- Bepreve, Bepotastine Besilate
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT02322216
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle
- Volunteers
- 383 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:
- Trial name
- NCT05579730
- Testing
- Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035%
- Where
- 4 sites in United States
- Volunteers
- 188 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
The present study will test if administration of different concentrations of 1334H eyedrops will be effective in treatment of allergic conjunctivitis in people with 10 yrs of age or older.
- Trial name
- NCT01320553
- Testing
- SPARC1102 I, SPARC1102 II, SPARC1102 III
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Sun Pharma Advanced Research Company Limited